|Report ID : RC-3017||Category : Healthcare||Published Date : 2018|
|Publisher : S-AND-P||Pages : 110||Format : PDF|
This report studies the global market size of Paclitaxel Injection in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Paclitaxel Injection in these regions. This research report categorizes the global Paclitaxel Injection market by players/brands, region, type and application. This report also studies the global market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels, distributors and Porter's Five Forces Analysis. Paclitaxel Injection is a kind of anti-cancer injection taking paclitaxel API as raw material. It is mainly used in breast cancer, ovarian cancer and other cancers. Paclitaxel injection comes as a liquid to be given intravenously (into a vein) by a doctor or nurse in a hospital or clinic. It is usually given once every 3 weeks. When paclitaxel injection manufactured with polyoxyethylated castor oil is used to treat Kaposi's sarcoma, it may be given once every 2 or 3 weeks. In recent years, the growing population and increasing disease incidence of ovarian cancer, breast cancer and other cancers drive the global paclitaxel injection industry developing. In the past five years from 2010-2014, global paclitaxel injection industry developed fast with a larger than 15% annual production growth rate. In China, due to the late start, the production growth rate is 12%~17%, which is a little lower than global average. In the next few years, with the growing attention on women cancers from the whole society and much larger investment on R&D of paclitaxel injection, this industry will continue developing at a high speed. What’s more, because of the high gross profit of producing and selling paclitaxel injection, more and more investors will enter into this industry. At present, the production of paclitaxel injection mainly concentrated in US, China and EU, the three regions produced about 77.30% of the global total products. Of those, US are the largest production region with a 42.69% of global production market share. In the future, with the expanded capacity of paclitaxel injection, the manufacturers will face the high risk of price and gross margin decline. In 2017, the global Paclitaxel Injection market size was 2180 million US$ and is forecast to 4560 million US in 2025, growing at a CAGR of 11.1% from 2018. The objectives of this study are to define, segment, and project the size of the Paclitaxel Injection market based on company, product type, application and key regions. The various contributors involved in the value chain of Paclitaxel Injection include manufacturers, suppliers, distributors, intermediaries, and customers. The key manufacturers in the Paclitaxel Injection include Bristol-Myers Squibb Celgene Corporation Hospira Biological E. Taj Accura Khandelwal Laboratories Luye Pharma Beijing Youcare Beijing Union Haiyao Chuntch Market Size Split by Type Drug Strength Raw meterial Paclitaxel API source Market Size Split by Application Ovarian cancer Breast cancer Cervical cancer Pancreatic cancer Other Market size split by Region North America United States Canada Mexico Asia-Pacific China India Japan South Korea Australia Indonesia Singapore Malaysia Philippines Thailand Vietnam Europe Germany France UK Italy Spain Russia Central & South America Brazil Rest of Central & South America Middle East & Africa GCC Countries Turkey Egypt South Africa The study objectives of this report are: To study and analyze the global Paclitaxel Injection market size (value & volume) by company, key regions/countries, products and application, history data from 2013 to 2017, and forecast to 2025. To understand the structure of Paclitaxel Injection market by identifying its various subsegments. To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks). Focuses on the key global Paclitaxel Injection manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years. To analyze the Paclitaxel Injection with respect to individual growth trends, future prospects, and their contribution to the total market. To project the value and volume of Paclitaxel Injection submarkets, with respect to key regions (along with their respective key countries). To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market. To strategically profile the key players and comprehensively analyze their growth strategies. In this study, the years considered to estimate the market size of Paclitaxel Injection are as follows: History Year: 2013-2017 Base Year: 2017 Estimated Year: 2018 Forecast Year 2018 to 2025 This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Paclitaxel Injection market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources. For the data information by region, company, type and application, 2017 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents 1 Study Coverage 1.1 Paclitaxel Injection Product 1.2 Key Market Segments 1.3 Key Manufacturers Covered 1.4 Market by Type 1.4.1 Global Paclitaxel Injection Market Size Growth Rate by Type 1.4.2 Drug Strength 1.4.3 Raw meterial Paclitaxel API source 1.5 Market by Application 1.5.1 Global Paclitaxel Injection Market Size Growth Rate by Application 1.5.2 Ovarian cancer 1.5.3 Breast cancer 1.5.4 Cervical cancer 1.5.5 Pancreatic cancer 1.5.6 Other 1.6 Study Objectives 1.7 Years Considered 2 Executive Summary 2.1 Global Paclitaxel Injection Market Size 2.1.1 Global Paclitaxel Injection Revenue 2016-2025 2.1.2 Global Paclitaxel Injection Sales 2016-2025 2.2 Paclitaxel Injection Growth Rate by Regions 2.2.1 Global Paclitaxel Injection Sales by Regions 2.2.2 Global Paclitaxel Injection Revenue by Regions 3 Breakdown Data by Manufacturers 3.1 Paclitaxel Injection Sales by Manufacturers 3.1.1 Paclitaxel Injection Sales by Manufacturers 3.1.2 Paclitaxel Injection Sales Market Share by Manufacturers 3.1.3 Global Paclitaxel Injection Market Concentration Ratio (CR5 and HHI) 3.2 Paclitaxel Injection Revenue by Manufacturers 3.2.1 Paclitaxel Injection Revenue by Manufacturers (2016-2018) 3.2.2 Paclitaxel Injection Revenue Share by Manufacturers (2016-2018) 3.3 Paclitaxel Injection Price by Manufacturers 3.4 Paclitaxel Injection Manufacturing Base Distribution, Product Types 3.4.1 Paclitaxel Injection Manufacturers Manufacturing Base Distribution, Headquarters 3.4.2 Manufacturers Paclitaxel Injection Product Category 3.4.3 Date of International Manufacturers Enter into Paclitaxel Injection Market 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans 4 Breakdown Data by Type 4.1 Global Paclitaxel Injection Sales by Type 4.2 Global Paclitaxel Injection Revenue by Type 4.3 Paclitaxel Injection Price by Type 5 Breakdown Data by Application 5.1 Overview 5.2 Global Paclitaxel Injection Breakdown Data by Application 6 North America 6.1 North America Paclitaxel Injection by Countries 6.1.1 North America Paclitaxel Injection Sales by Countries 6.1.2 North America Paclitaxel Injection Revenue by Countries 6.1.3 United States 6.1.4 Canada 6.1.5 Mexico 6.2 North America Paclitaxel Injection by Type 6.3 North America Paclitaxel Injection by Application 6.4 North America Paclitaxel Injection by Company 7 Europe 7.1 Europe Paclitaxel Injection by Countries 7.1.1 Europe Paclitaxel Injection Sales by Countries 7.1.2 Europe Paclitaxel Injection Revenue by Countries 7.1.3 Germany 7.1.4 France 7.1.5 UK 7.1.6 Italy 7.1.7 Russia 7.2 Europe Paclitaxel Injection by Type 7.3 Europe Paclitaxel Injection by Application 7.4 Europe Paclitaxel Injection by Company 8 Asia Pacific 8.1 Asia Pacific Paclitaxel Injection by Countries 8.1.1 Asia Pacific Paclitaxel Injection Sales by Countries 8.1.2 Asia Pacific Paclitaxel Injection Revenue by Countries 8.1.3 China 8.1.4 Japan 8.1.5 Korea 8.1.6 India 8.1.7 Australia 8.1.8 Indonesia 8.1.9 Malaysia 8.1.10 Philippines 8.1.11 Thailand 8.1.12 Vietnam 8.1.13 Singapore 8.2 Asia Pacific Paclitaxel Injection by Type 8.3 Asia Pacific Paclitaxel Injection by Application 8.4 Asia Pacific Paclitaxel Injection by Company 9 Central & South America 9.1 Central & South America Paclitaxel Injection by Countries 9.1.1 Central & South America Paclitaxel Injection Sales by Countries 9.1.2 Central & South America Paclitaxel Injection Revenue by Countries 9.1.3 Brazil 9.2 Central & South America Paclitaxel Injection by Type 9.3 Central & South America Paclitaxel Injection by Application 9.4 Central & South America Paclitaxel Injection by Company 10 Middle East and Africa 10.1 Middle East and Africa Paclitaxel Injection by Countries 10.1.1 Middle East and Africa Paclitaxel Injection Sales by Countries 10.1.2 Middle East and Africa Paclitaxel Injection Revenue by Countries 10.1.3 GCC Countries 10.1.4 Turkey 10.1.5 Egypt 10.1.6 South Africa 10.2 Middle East and Africa Paclitaxel Injection by Type 10.3 Middle East and Africa Paclitaxel Injection by Application 10.4 Middle East and Africa Paclitaxel Injection by Company 11 Company Profiles 11.1 Bristol-Myers Squibb 11.1.1 Bristol-Myers Squibb Company Details 11.1.2 Company Description 11.1.3 Sales, Revenue and Gross Margin of Paclitaxel Injection 11.1.4 Paclitaxel Injection Product Description 11.1.5 Recent Development 11.2 Celgene Corporation 11.2.1 Celgene Corporation Company Details 11.2.2 Company Description 11.2.3 Sales, Revenue and Gross Margin of Paclitaxel Injection 11.2.4 Paclitaxel Injection Product Description 11.2.5 Recent Development 11.3 Hospira 11.3.1 Hospira Company Details 11.3.2 Company Description 11.3.3 Sales, Revenue and Gross Margin of Paclitaxel Injection 11.3.4 Paclitaxel Injection Product Description 11.3.5 Recent Development 11.4 Biological E. 11.4.1 Biological E. Company Details 11.4.2 Company Description 11.4.3 Sales, Revenue and Gross Margin of Paclitaxel Injection 11.4.4 Paclitaxel Injection Product Description 11.4.5 Recent Development 11.5 Taj Accura 11.5.1 Taj Accura Company Details 11.5.2 Company Description 11.5.3 Sales, Revenue and Gross Margin of Paclitaxel Injection 11.5.4 Paclitaxel Injection Product Description 11.5.5 Recent Development 11.6 Khandelwal Laboratories 11.6.1 Khandelwal Laboratories Company Details 11.6.2 Company Description 11.6.3 Sales, Revenue and Gross Margin of Paclitaxel Injection 11.6.4 Paclitaxel Injection Product Description 11.6.5 Recent Development 11.7 Luye Pharma 11.7.1 Luye Pharma Company Details 11.7.2 Company Description 11.7.3 Sales, Revenue and Gross Margin of Paclitaxel Injection 11.7.4 Paclitaxel Injection Product Description 11.7.5 Recent Development 11.8 Beijing Youcare 11.8.1 Beijing Youcare Company Details 11.8.2 Company Description 11.8.3 Sales, Revenue and Gross Margin of Paclitaxel Injection 11.8.4 Paclitaxel Injection Product Description 11.8.5 Recent Development 11.9 Beijing Union 11.9.1 Beijing Union Company Details 11.9.2 Company Description 11.9.3 Sales, Revenue and Gross Margin of Paclitaxel Injection 11.9.4 Paclitaxel Injection Product Description 11.9.5 Recent Development 11.10 Haiyao 11.10.1 Haiyao Company Details 11.10.2 Company Description 11.10.3 Sales, Revenue and Gross Margin of Paclitaxel Injection 11.10.4 Paclitaxel Injection Product Description 11.10.5 Recent Development 11.11 Chuntch 12 Market Opportunities, Challenges, Risks and Influences Factors Analysis 12.1 Market Opportunities and Drivers 12.2 Market Challenges 12.3 Market Risks/Restraints 12.4 Key World Economic Indicators 13 Value Chain and Sales Channels Analysis 13.1 Value Chain Analysis 13.1.1 Typical Suppliers of Key Paclitaxel Injection Raw Material 13.1.2 Paclitaxel Injection Customers 13.2 Sales Channels Analysis 13.2.1 Sales Channels Analysis 13.2.2 Distributors 14 Research Findings and Conclusion 15 Appendix 15.1 Research Methodology 15.1.1 Methodology/Research Approach 126.96.36.199 Research Programs/Design 188.8.131.52 Market Size Estimation 184.108.40.206 Market Breakdown and Data Triangulation 15.1.2 Data Source 220.127.116.11 Secondary Sources 18.104.22.168 Primary Sources 15.2 Author Details 15.3 Disclaimer
Akasaka biz tower,
5-3-1 akasaka minato-ku,
13284 bluejacket street overland park,
KS 66213 United States